Publications (21) Sara Villar Fernández publications

filter_list

2025

  1. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

    Blood Cancer Journal, Vol. 15, Núm. 1

2024

  1. Cardiac events after allo-HCT in patients with acute myeloid leukemia

    Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509

  2. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703

  3. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care

    Frontiers in Immunology, Vol. 15

  4. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

    Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Disseminated lymphadenopathy during chemotherapy for squamous cell lung carcinoma

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 7, pp. 438-440

  3. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  4. Low Rate of Infectious Enterocolitis in Allogeneic Stem Cell Transplant Recipients with Acute Diarrhea: A Prospective Study by the GETH-TC

    Acta haematologica, Vol. 146, Núm. 2, pp. 161-165

  5. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

  6. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Explainable artificial intelligence for precision medicine in acute myeloid leukemia

    Frontiers in Immunology, Vol. 13

  2. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 703.e1-703.e8

  3. Successful cefiderocol therapy of severe infections due to difficult-to-treat Pseudomonas aeruginosa in two allogeneic hematopoietic stem cell transplantation recipients

    Annals of Hematology

  4. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

    Frontiers in Oncology, Vol. 12

  5. Updates on the Management of Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 19

2021

  1. Allogeneic Stem Cell Transplantation for MDS

    Hemato, Vol. 2, Núm. 3, pp. 545-555

  2. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

2018

  1. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity

    Haematologica

2012

  1. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1453-1458